Tech Bundle

AI In Healthcare

Artificial Intelligence (AI) in healthcare explores the AI systems which can be consisted of sensors, AI hardware and AI software. Sensors explore detection tools that integrated with AI system to diagnose and monitor one’s health. AI Hardware explores the chipset design and architecture, rather than algorithms, to achieve the next big breakthrough in AI. AI software explores computer program which mimics human behaviour by learning various data patterns and insights. Shaped by the AI systems, AI-powered technologies and its applications, such as personalized implants, AI-assisted personalized rehabilitation, AI-assisted robotic surgery, wireless body sensor networks and AI-powered assistive technologies may soon become a reality.

Non-invasive Prostate Cancer Detection Device
A biosensor for the selective capture and detection of prostate cancer cells in urine Prostate cancer is the most commonly diagnosed cancer in men and, while a range of invasive and non-invasive diagnostic tests exist, identifying aggressive and life-threatening cases is a real challenge. For example, the poor specificity of PSA blood tests (prostate specific antigen) leads to overdiagnosis and overtreatment. More than 600,000 PSA tests are performed in Australia each year. The results of the PSA test prescribe in excess of 25,000 invasive and painful prostate biopsies (trans-rectal or trans-perineal), each of them costing around $2,000 to Medicare ($50M p.a) while in 70% of cases, no cancer is found. The spontaneous shedding of prostate cancer cells into urine provides non-invasive potential for the establishment of more accurate prostate cancer routine diagnostics.
Multi-sensing Nanoscale Biochips
Electrochemical and optical biosensors, which are dominant technologies in the global biosensor market, have the disadvantage of long assay time, labelling, sophisticated infrastructure and expensive reagents in point-of-care diagnostic assay. The micro/nanofabrication technologies and the discovery of abundant nanoscale materials have now opened up new possibilities for developing novel bioelectronic sensors, which are sensitive, robust, portable, and inexpensive and hold great potential for applications in a wide variety of areas, ranging from diagnosis of life-threatening diseases to point-of-care diagnosis. The multi-sensing nanoscale biochips is a platform for assembling different molecular building-blocks between independent carbon nanoelectrodes in order to allow ultrahigh sensitivity with simultaneous detection of multiple biological targets on a single-biochip at low fabrication costs. It could also provide a biocompatible and flexible platform for the low cost fabrication of miniaturized bio-sensing devices with applications in wearable and/or implantable products. 
Wireless Sensing (WISE) Platform for On-demand Monitoring of Post-surgical Complication
A wireless sensing (WISE) platform has been successfully developed for real-time, continuous monitoring of post-surgical complications like bleeding, infection, compromise in suture integrity etc., even before the symptoms of the complications appear. The platform consists of implantable WISE tags that can be clipped on like a ‘pick-and-place sensor’ to any suture after suturing, in a surgeon-proof method and a handheld WISE reader that can communicate the changes at the deep surgical sites.
Digital Foam - A Touch Sensitive Foam Surface
Our researchers have developed a ‘Digital Foam’ material that recognizes and responds to touch. The foam material is highly flexible and can accurately detect multiple simultaneous deformations in its surface. Several applications for Digital Foam are anticipated, from an augmented reality controller and home entertainment games controllers, to medical mannequins used for training surgeons and doctors.
60GHz Compact Radar for Vital Signs Monitoring
This technology offer is a 60GHz compact radar, which is the smallest in the world. The radar is able to detect the respiration rate and heart of occupants, thereby giving it a broad range of possible applications such as contactless vital signs monitoring and people counting. It can be used inside vehicles to perform: ROA (Rear Occupancy Alerts) DMS (Driver Monitoring System)
Fast and Cost-efficient AI Platform to Optimise Combination Therapy and Media Formulation
The current approach to drug discovery is hypotheses driven, and combination therapies have preset biasness from a few factors such as mechanisms of actions, literature reviews and scientific panels. This results in one lead molecule usually only being tested with one to two other drugs for particular indications. The team holds IP that allows assessment of hundreds of drugs with lead molecules that are tested and validated against multiple indications through a proprietary AI platform. This platform, combined with automated experiments and proprietary arrays, allows for optimal drug discovery more effectively and efficiently. The technology is also applicable for media formulation, whereby optimal media for bio-processes/cell culture can be designed using the platform.
Point-of-care Bacteria Infection Identification Device
A start-up company has developed an electrochemical sensing technology that is able to detect bacterial cells in less than two minutes, which is useful for the diagnosis of bacterial infections at the point-of-care. By measuring and identifying the unique metabolites excreted by each bacteria cell, the patented technology offers an improved magnitude sensitivity of four orders compared to the slower and more cumbersome method of direct cell detection. The handheld electrochemical sensing device only requires a sample size of 7.5 μL of any biological fluid with zero sample preparation or incubation needed to be effective. This makes it an immediate and reliable method for accurate diagnosis with no need of a central lab for processing. The initial target is in the veterinary diagnostics markets and, in particular, for the diagnosis of ear infections. Tests for other infectious diseases are also being developed.
Bioinformatics Platform Solution for Clinical, Research Oncology and Pharmacogenomics
A Singapore healthcare technology startup is offering an integrated bioinformatics platform solution specialising in oncology, pharmacogenomics (PGx) and infectious diseases to facilitate higher clinical and research precision. Integrating a manually curated clinical-genomics knowledge database, real-world datasets, advanced machine learning analysis and intuitive application and reporting tools in one workflow, the bioinformatics platform solution utilises and analyses medical big data for precise, personalised and data-driven results, improving outcomes in patient care and drug discovery.
Automated Diagnosis of Normal/Abnormal Fundus Image using Convolutional Neural Network
Fundus photography is one of the imaging techniques commonly adopted in eye clinics for the diagnosis of main eye diseases that ultimately leads to blindness, Age-Related Macular Degeneration (AMD), Diabetic Retinopathy (DR) and Glaucoma. However, manual assessment of fundus images is time-consuming and subjective. Frequent eye screening of the elderly put pressures on an already resource-tight medical system.  The technology is trained and tested on a convolutional neural network that automatically classifies images of age-related macular degeneration (AMD), diabetic retinopathy (DR) and glaucoma as abnormal and images of normal subjects as normal.